- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 730360, 12 pages
Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
Department of Medical Oncology/Hematology, Cancer Center, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
Received 1 November 2010; Revised 4 March 2011; Accepted 16 June 2011
Academic Editor: J. B. Vermorken
Copyright © 2011 Toru Mukohara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2) protein, mainly as a result of gene amplification. The receptor tyrosine kinase is believed to play a critical role in the pathogenesis and further proliferation of these tumors. The application of trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, to HER2-positive metastatic breast cancer has significantly improved treatment outcomes. Following this success, several phase III trials have evaluated the role of trastuzumab in the adjuvant setting, with the result that trastuzumab use is now the standard of care for most HER2-positive early breast cancer patients. In this paper, we review these pivotal phase III trials. We also discuss unresolved issues in adjuvant treatment with trastuzumab, including target patient population, sequential or concurrent use with chemotherapy or radiation, treatment duration, cardiotoxicity, and the possibility of eliminating chemotherapy. Following confirmation of its ability to partially overcome trastuzumab resistance, we also discuss the role of lapatinib in adjuvant use.
Breast cancer is the leading cause of cancer death among women worldwide, with approximately one million new cases reported each year [1, 2]. Approximately 20% of breast cancer tumors show overexpression of human epidermal growth factor receptor 2 (HER2) protein, which has been repeatedly identified as a poor prognostic factor [3, 4]. Trastuzumab, a humanized monoclonal antibody which targets the extracellular domain of the HER2 protein, has undergone intense clinical investigation since the late 1990s. Clinical development of trastuzumab was initially focused on treatment for HER2-positive metastatic breast cancers in the mid-1990s. In the first pivotal phase III study, patients were treated with doxorubicin or epirubicin and cyclophosphamide (AC or EC) or paclitaxel with or without trastuzumab . Results for the trastuzumab-containing arm were superior to those with chemotherapy alone in virtually all efficacy parameters assessed, including overall survival (median, 25.1 versus 20.3 months, ; HR, 0.80) , which, together with the results of other studies, led to the broad clinical adoption of trastuzumab in single or combined use with anthracyclines, taxanes, vinorelbine, or capecitabine for HER2-positive metastatic breast cancer [6–8]. Following this success in the metastatic setting, ongoing evaluation of trastuzumab in adjuvant settings for operable HER2-positive breast cancers was started, and with the six randomized phase III trials of the integration of trastuzumab into standard adjuvant treatments completed to date, all but one reporting that the addition of trastuzumab provided a significant improvement in efficacy [9–16].
In this paper, we discuss the current status of trastuzumab therapy in adjuvant treatment for breast cancer. We also discuss unresolved issues in adjuvant use, including target patient population, sequential or concurrent use with chemotherapy, duration of treatment, cardiotoxicity, and the possibility of eliminating chemotherapy. Given that lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase, has been clinically proven to overcome at least some resistance to trastuzumab in the metastatic setting , we also discuss the potential role of lapatinib in adjuvant treatment, along with the current status of a large ongoing randomized study.
2. Pathophysiology of the HER Family in Breast Cancer
HER2 is a receptor tyrosine kinase (RTK) belonging to the HER family which consists of HER 1 through 4. With the exception of HER2, each member of the HER family has cognate-identified ligands. Ligand binding to extracellular domains induces conformational changes in the receptor, which enable the receptor to form a homo- or heterodimer and to become active as an RTK. Each dimer can subsequently trigger various intracellular signaling pathways, including those of PI3K/Akt, Ras/Raf/MEK/ERK, and STATs, which all play important roles in cellular oncogenic processes such as proliferation, survival, motility, and angiogenesis.
Because of the lack of a cognate ligand, HER2 must dimerize with other HER family members under physiological conditions. HER2 is considered to be the preferred dimerization partner for the other HER family members. In addition, under conditions of overexpression, HER2 can be constitutively active and transform normal cells in the absence of a ligand [18, 19]. While HER2 can theoretically form four different types of dimers, namely, with HER1, HER2, HER3, or HER4, the HER2/HER3 heterodimer is considered to be the most mitogenic and transforming [20–23].
HER2 is overexpressed in 20%–25% of breast cancers. In preclinical studies, HER2 overexpression has been shown to be associated with increased metastatic potential  and resistance to chemotherapeutic drugs such as paclitaxel, docetaxel, doxorubicin, 5-fluorouracil, and etoposide [25, 26]. Clinically, HER2-overexpression has been shown to be associated with poor disease-free survival and overall survival, and poor responsiveness to CMF- (cyclophosphamide, methotrexate, and 5-fluorouracil) like therapy [3, 4, 27, 28]. Gene amplification is considered the main mechanism of HER2 protein overexpression. HER2 has been reported to require HER3 to drive breast cancer cell proliferation, emphasizing the importance of the HER2/HER3 heterodimer complex mentioned above .
3. Mechanisms of Action of Trastuzumab
The mechanisms of action for trastuzumab can be roughly divided into two categories: inhibition of intracellular signaling and induction of an immune system-mediated antitumor response. Given HER2’s effect in triggering multiple signaling pathways, its inhibition should theoretically lead to the inactivation of those pathways. Although it is not fully understood how trastuzumab inhibits HER2 activity, some studies have suggested that the drug might promote internalization and degradation of HER2 [30, 31]. Recent studies have suggested that the HER2/HER3/PI3K complex and subsequent PI3K-Akt signaling pathway play central roles in cell proliferation in HER2-overexpressing cells and that the disruption of this complex might accordingly be the key molecular mechanism of action of trastuzumab [32, 33]. Supporting the involvement of PI3K-Akt pathway in trastuzumab action, studies suggested that activating mutation of the PIK3CA gene, which codes the p110α catalytic domain of PI3K, or loss of phosphatase and tensin homolog deleted from chromosome 10 (PTEN), could cause resistance to trastuzumab [34–36].
Data from several in vivo experiments have indicated that trastuzumab is capable of mediating the induction of immune responses such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity . With ADCC, immunoeffector cells expressing the Fcγ receptor recognize and bind to the Fc domain of the IgG1 antibody (trastuzumab) and subsequently lyse cells (in this case, tumor cells) attached to the antibody. Directly proving the role of ADCC in trastuzumab’s activity is naturally difficult in patients. However, perhaps the most convincing evidence of the contribution of ADCC to trastuzumab-induced antitumor activity was provided by mice lacking the FC receptor (FcR-/-), in which trastuzumab treatment resulted in significantly lower rates of tumor regression than in FC receptor-expressing mice .
4. Role of Trastuzumab in Adjuvant Treatment for Early Breast Cancer
4.1. Overview of Pivotal Phase III Randomized Trials
Following its successful application in HER2-positive metastatic breast cancer, trastuzumab was subsequently tested in adjuvant use. As of today, the results of six well-designed phase III trials comparing nontrastuzumab adjuvant therapies with trastuzumab-containing therapies are available in either conference abstract form or full paper (Table 1 and Figure 1).
The National Surgical Adjuvant Breast and Bowel Project trial B-31 (NSABP B-31) compared four cycles of doxorubicin and cyclophosphamide (AC) followed by four cycles of triweekly paclitaxel (tri-PTX) (Arm 1, reference arm) with the same regimen plus 52 weeks of weekly trastuzumab (wkly-HER) beginning on day 1 of tri-PTX (Arm 2) (Figure 1) [10, 13]. Women with estrogen-receptor- (ER) positive or progesterone-receptor- (PgR) positive tumors received 20 mg of tamoxifen per day for five years. Tamoxifen was originally initiated on day 1 of the first cycle of AC, but this was amended in response to the findings of Southwest Oncology Group trial 8814 to require that hormonal therapy be started after chemotherapy . A second amendment following the report of the arimidex, tamoxifen alone or in combination (ATAC) trial permitted treatment with anastrozole in postmenopausal ER- or PgR-positive patients . The North Central Cancer Treatment Group trial N9831 (NCCTG N9831) compared four cycles of AC followed by 12 weeks of weekly paclitaxel (wkly-PTX) (Arm A, reference arm) with the same regimen plus 52 weeks of wkly-HER either following wkly-PTX (Arm B) or beginning on day 1 of wkly-PTX (Arm C) (Figure 1) [10, 41]. Women with ER- or PgR-positive tumors were originally scheduled to receive 20 mg of tamoxifen per day for five years, initiated after chemotherapy. Following the ATAC trial, however, the protocol was amended to permit postmenopausal ER- or PgR-positive patients to be treated with any aromatase inhibitor. Because of the similarity of Arms 1 and 2 in the NSABP B-31, and Arms A and C in the NCCTG N9831, combined analysis was performed and the results were published as a full paper , with subsequent updated data available in a conference abstract form . Individual data of the NCCTG N9831 is only available as a conference abstract at this time [41, 42].
The Breast Cancer International Research Group 006 (BCIRG 006) compared four cycles of AC followed by four cycles of triweekly docetaxel (tri-DTX) (reference arm) with the same regimen plus 52 weeks of trastuzumab (weekly at DTX phase and triweekly thereafter) beginning on day 1 of tri-DXT (Figure 1). This trial is distinguished from the others by the involvement of a nonanthracycline regimen, consisting of docetaxel, carboplatin, and trastuzumab (TCH), with the aim of reducing cardiotoxicity [11, 12]. The results of this study are presently available only as a conference abstract [11, 12].
The Herceptin Adjuvant (HERA) study differed from the other trials in that patients were randomized at the point of completion of standard adjuvant chemotherapy with or without radiotherapy to either observation alone, one year of triweekly trastuzumab (tri-HER), or two years of tri-HER (Figure 1) [9, 14]. Adjuvant endocrine therapy, primarily 20 mg of tamoxifen per day, was given after chemotherapy to women with ER- or PgR-positive disease. An amendment to the protocol allowed aromatase inhibitors to be used instead of or in sequence with tamoxifen . Initial and two follow-up data from observation and one year of trastuzumab were published in 2005, 2007, and 2011, respectively [9, 14, 43]. Data from two years of trastuzumab is not available at this point.
The Finland Herceptin (FinHER) study was designed to compare three cycles of triweekly vinorelbine with tri-DXT, both followed by three cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) (Figure 1) [15, 16]. For HER2-positive patients, patients were additionally randomized at the tri-VNR or tri-DXT phase to receive or not receive tri-HER. Patients with ER- or PgR-positive tumors initially received 20 mg of tamoxifen per day for five years. The protocol was amended during the trial to allow the switching of tamoxifen to an aromatase inhibitor for postmenopausal women after 2 to 3 years of tamoxifen use to complete the 5-year administration of a hormonal agent and to allow administration of an aromatase inhibitor for a further 2 to 3 years after the completion of 5-year administration of tamoxifen . Distinct from the other trials, trastuzumab was given for only nine weeks in this study. Initial results were published in 2006 and the final results in 2009 [15, 16].
The Programmes d’Actions Concertées Sein (PACS) 04 trial first randomly assigned patients to six courses of fluorouracil, epirubicin 100 mg/m2, and cyclophosphamide (FEC100) or six courses of epirubicin 75 mg/m2 and docetaxel (ED75) and then further randomized HER2-positive patients to sequential tri-HER for 1 year or to observation (Figure 1) . Endocrine therapy was mandatory for patients with ER- or PgR-positive tumors. Premenopausal patients were given 20 mg of tamoxifen per day for 5 years, while postmenopausal patients received endocrine therapy with either anastrozole or tamoxifen at the discretion of investigator .
4.2. Efficacy Data
Although the PACS 04 trial enrolled only node-positive patients, other baseline characteristics of the disease were quite similar between the six trials (Table 1). All six trials established recurrence-free survival (RFS) (FinHER) or disease-free survival (DFS) (the others) as the primary endpoint with subtle difference in the definition regarding whether to count ductal carcinoma in situ (DCIS) or second nonbreast malignancy as an event [9, 10, 16]. Although in the final report of the FinHER study the primary endpoint was amended to be distant disease-free survival , we adopted the efficacy data from the initial report in Table 1 for better comparison between the trials.
All but the PACS 04 study showed the superiority of trastuzumab-containing regimens over standard regimens without trastuzumab, with statistical significance, with the most recent hazard ratios (HRs) ranging from 0.42 to 0.76 (Table 1) [12–14, 16, 41, 44]. In PACS 04, trastuzumab did not significantly improve DFS with HR of 0.86 (95% CI 0.61–1.27; ) . Overall survival (OS), set as a secondary endpoint in each trial, tended to be improved with trastuzumab-containing regimens compared to nontrastuzumab regimens, again with the exception of the PACS 04 trial (Table 1). The most recent HRs for OS in trials other than PACS 04 ranged from 0.41 to 0.86, and values were less than 0.05, except for those for Arm B (sequential trastuzumab) in the NCCTG N9831, and trastuzumab-containing regimens employed in the HERA and FinHER studies (Table 1) [12–14, 16, 41, 44]. HR for OS in PACS 04 was 1.27 with the wide 95% CI of 0.68–2.38, possibly due to small sample size (Table 1).
4.3. Target Patients for Treatment with Trastuzumab
4.3.1. HER2 Measurement
With the clinical development of anti-HER2 agents, including trastuzumab, methods for evaluating the expression level of HER2 has also evolved. In the six trastuzumab adjuvant trials, HER2 positivity was evaluated with immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), or chromogenic in situ hybridization (CISH), either alone or on combination. All six trials stipulated that central confirmation of HER2-positivity using these methods was mandatory either from the beginning or after protocol amendment [44, 45].
IHC is a semiquantitative method which detects HER2 protein levels on the cell surface in breast cancer specimens. Currently, the US Food and Drug Administration (FDA) has approved three types of IHC system to determine HER2 status: HercepTest (Dako, Glostrup, Denmark), Pathway anti-HER2/neu (Clone CB11) (Ventana-Roche, Tucson, Ariz, USA), and InSite HER2/neu CB11 (Biogenex, San Ramon, Calif, USA). In each system, IHC scoring is performed subjectively as 0, 1+, 2+, or 3+ based on the intensity of membrane staining in >10% of cancer cells .
FISH or CISH is a DNA-based assay that directly measures HER2 gene amplification. FISH testing results are semiquantitative, based on the absolute number of HER2 signals or the average ratio of HER2 signals to CEP17 (a probe against the chromosome 17 centromeric sequences) signals in nonoverlapping interphase nuclei of the lesion. The FDA has approved three types of FISH testing: PathVysion (Vysis, Downers Grove, Ill, USA), in which a ≥2.0 ratio HER2/CEP17 is considered amplified; INFORM (Ventana-Roche), in which ≥5.0 gene copies of HER2 is considered amplified; and HER2 FISH pharmDx (Dako), in which a ≥2.0 ratio of HER2/CEN-17 is considered amplified. In addition, one CISH test has been approved: SPOT-Light (Invitrogen, Carlsbad, Calif, USA), in which 10 dots, or large clusters, or a mixture of multiple dots and large clusters in 50% of tumor cells is considered amplified.
To improve the accuracy of HER2 testing and its utility as a predictive marker for anti-HER2 agents, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated their guideline recommendation for HER2 testing in 2007 . Positivity for HER2 is demonstrated by either IHC HER2 3+, defined as uniform intense membrane staining of >30% of invasive tumor cells or FISH amplified, defined as a ratio of HER2 to CEP17 >2.2, or an average HER2 gene copy number >6 signals/nucleus for those test systems without an internal control probe. They also recommend that if initial results for HER2 are equivocal, that is, HER2 2+, IHC or FISH ratio 1.8–2.2, or HER2 gene copy 4.0–6.0, validated IHC, FISH, or CISH should be performed or repeated.
It should be noted that the new ASCO/CAP HER2 positivity criteria are stricter than those of the manufacturers. In the five adjuvant trastuzumab trials with the exception of PACS 04, positive IHC membrane staining in 10% to less than 30% of cells and an HER2/CEP17 ratio of 2–2.2, were eligible based on the manufacturers’ criteria. In the PACS 04 trial, while the same manufacturers’ criteria were used for IHC, only IHC 2+ cases were sent to FISH and HER2/CEP17 ratio ≥2.2 was defined as positive . But, these cases would have been equivocal based on the ASCO/CAP guideline. To assess the influence of differential criteria on study result, tumor samples in the NCCTG N9831 were reevaluated using the ASCO/CAP criteria , but the results showed that only a small percentage (by IHC, 3.7%; FISH, 1.4%; both, 1.7%) of patients did not meet the ASCO/CAP 2007 HER2 positivity guidelines . Because there is no evidence to support that the patients with equivocal HER2 positivity should be excluded from adjuvant treatment with trastuzumab, the drug is generally given as a part of systemic therapy.
4.3.2. Definition of High Risk no Disease
Among the six trials, only the PACS 04 trial enrolled only node-positive patients, whereas the other five trials enrolled both node-positive and negative high-risk patients. However, they varied in their definition of high-risk. Both the NCCTG N9831 and NSABP B-31 trials defined tumors of more than 2 cm in diameter for hormone receptor- (HR-) positive disease and more than 1 cm in diameter for HR-negative disease as high risk (Table 1). The HERA study enrolled node-negative patients with primary tumors that were more than 1 cm regardless of HR status, while the BCIRG 006 trial considered high risk as node-negative disease with tumors that were either more than 2 cm in diameter, HR-negative, or histological grade (HG) 2 or 3, or with a patient age of younger than 35 years. Finally, the FinHER study enrolled node-negative patients with tumors that were more than 2 cm in diameter and PgR-negative. Of note, no trials involved node-negative disease with a primary tumor size of 1 cm or less, and no definitive threshold for treatment with or without trastuzumab has accordingly yet been established.
The often-utilized St Gallen International Expert Consensus, renewed in 2009, included the following statement: “patients with tumors of <1 cm in size without axillary nodal involvement and without other features indicating increased metastatic potential (e.g. vascular invasion) might not need adjuvant systemic therapy” . The National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline, on the other hand, recently raised its category of evidence and consensus from Category 3A (reflecting the presence of major disagreement among NCCN panel members) to Category 2A (based on a lower-evidence but uniform NCCN consensus) for consideration of adjuvant trastuzumab in women with node-negative tumors that are 0.6 to 1.0 cm (NCCN, Version 2, 2011). This update was based on several retrospective studies which suggested that HER2-positivity is a poor prognostic factor even in patients with node-negative tumors ≤1.0 cm [47–49]. The consideration of trastuzumab use for node-negative small tumors is also supported by a recently published article by Banerjee et al. . These authors reviewed retrospective studies which followed the outcome of patients with HER2-positive, node-negative, and 1 cm or smaller tumors . They found that while relapse in patients with HER2-positive small tumors was less than 10% at 10 years after diagnosis, it rose to 16% to 17% and 21% to 29% at 15 and 20 years after diagnosis, respectively, in those studies with long-term followup . They also noted that patients with relatively small tumors (1.1–2.2 cm) in the HERA study had the same magnitude of risk reduction with trastuzumab . Therefore, although a final decision on the used of trastuzumab in these patients should be left to clinical judgment, physicians should at least discuss this issue with patients.
4.4. Treatment Duration
In addition to one-year trastuzumab and reference arms, the HERA study also established a 2-year trastuzumab arm . No efficacy or safety data for this longer arm is yet available, so the value of administration beyond one year is unclear. The FinHER study was distinguished from the other large trials by its administration of trastuzumab for only 9 weeks, concurrently with vinorelbine or docetaxel [15, 16]. Despite this short duration, trastuzumab provided a dramatic improvement in efficacy over the nontrastuzumab control, with an HR of 0.42 for RFS . Multiple randomized trials comparing the standard 1 year of trastuzumab therapy with a shorter duration are ongoing. In one, the synergism or long duration (SOLD) Study conducted by the Finnish group following the FinHER trial, three cycles of tri-DXT in combination with wkly- or tri-HER followed by three cycles of FEC was compared with the same regimen followed by 14 doses of additional tri-HER to give a total duration of trastuzumab therapy of one year. Results of these trials will provide an insight into the optimal duration of adjuvant trastuzumab (NCT00593697). Until then, however, one-year trastuzumab should be considered the current standard, because this was the duration used by the majority of the randomized trials.
4.5. Concurrent or Sequential
Joint analysis of the NCCTG N9831 and NSABP B31 trials, which compared a nontrastuzumab control and trastuzumab given concurrently with paclitaxel, produced the impressive HR for DFS of 0.49 . The NCCTG N9831 involved another arm in which trastuzumab was given sequentially after the completion of wkly-PTX (Arm B, Figure 1). Individual data for this trial comparing reference Arm A (nontrastuzumab) with sequential arm (Arm B) is available in conference abstract form, and show an HR for Arm B of 0.67, which is somewhat less robust than that in the joint analysis of NCCTG N9831 and NSABP B31 trials . Further, the concurrent arm was superior to the sequential arm, with an HR for DFS of 0.75 (95% CI 0.60–0.94; )  even though this comparison was not the primary analysis of the NCCTG N9831. In addition, the HERA study, in which trastuzumab was given sequentially after completion of standard chemotherapy, again produced the less robust HR for DFS of 0.76, which is less than the joint analysis of the NCCTG N9831 and NSABP B31 trials. Further, in PACS 04 trial, trastuzumab given after completion of six courses of FEC100 or ED did not provide any significant impact on DFS compared to observation. Therefore, it is very likely that trastuzumab is more active when given concurrently with than sequentially after chemotherapy as long as the same chemotherapy regimen is employed.
Although trastuzumab is generally very well tolerated, it occasionally impairs cardiac function due to myocardium damage. While anthracycline-induced cardiotoxicity is dose-dependent and results mainly from oxidative mechanisms that lead to the apoptosis and necrosis of cardiomyocytes, trastuzumab-induced cardiotoxicity is generally not dose-dependent and does not show the ultrastructural changes typical of anthracycline [51, 52]. Although the mechanism of trastuzumab-associated cardiac dysfunction is not precisely known, it has been suggested that HER2 may have a protective role for cardiomyocytes . No consistent risk factors for trastuzumab-associated cardiotoxicity have been identified, out older age and need for antihypertensive agents baseline left ventricular ejection fraction (LVEF) <55% were found to be associated with incidence of cardiac events in the NCCTG N9831 and NSABP B31 trials [54, 55].
As summarized in Figure 1, the incidence of cardiac dysfunction and severe chronic heart failure (CHF) in trastuzumab-containing treatment in the phase III trials ranged from 3.0% to 14.2% and from 0.4% to 3.8%, respectively. Given their differing definitions of cardiac dysfunction and severe CHF, direct comparison between regimens requires prudence. Nevertheless, when we see much lower incidence of cardiotoxicity in the HERA study than that in the NSABP B-31 study, it appears that a high incidence of cardiotoxicity should be expected when trastuzumab is given concurrently with chemotherapy (Figure 1). On the other hand, the direct comparison of concurrent versus sequential administration of trastuzumab in the NCCTG N9831 showed only minimally reduced cardiotoxicity in the latter . The PACS 04 trial also had high incidence of systolic dysfunction despite sequential administration of trastuzumab after completion of six cycles of FEC100 or ED75 . Considering the fact that in the HERA study only one-fourth of patients took taxanes before trastuzumab and median cumulative dose of anthracyclines were relatively low (238 and 405 mg/m2 for doxorubicin and epirubicin, respectively), high dose of anthracycline and a taxane before initiating sequential trastuzumab may be associated with higher cardiotoxicity. Relevant to this, trastuzumab was given before anthracycline-based chemotherapy in the FinHER study only, which had a very low incidence of severe CHF (one patient) . Although this may have been caused by the shorter duration of trastuzumab therapy than in the other trials, as discussed below, this, nevertheless, supports the possibility that trastuzumab after anthracycline therapy hampers the heart's repair mechanisms.
In the BCIRG 006 trial, a nonanthracycline regimen (TCH) was included owing to concerns of cardiotoxicity caused by trastuzumab use following anthracycline. This regimen was indeed associated with lower cardiotoxicity than those containing anthracycline [11, 12]. It should be noted, however, that decrease in risk with TCH appears somewhat smaller than that with AC followed by docetaxel/trastuzumab (HR for DFS, AC followed by docetaxel/trastuzumab versus TCH, 0.64 versus 0.75), notwithstanding that the trial was not designed to compare these two regimens .
Another potential approach to avoiding trastuzumab-associated cardiotoxicity is to shorten the duration of therapy, as attempted in the FinHER study. These investigators appear to have achieved this particular goal, with even a lower incidence of systolic dysfunction and symptomatic CHF in the HER2-containing arm than in the nontrastuzumab control arm . As discussed above, however, the degree to which duration can be shortened without decrementing efficacy remains unknown.
Radiation after breast surgery has been considered a cardiac risk. While in the HERA and PACS 04 studies and the FinHER study postsurgical radiotherapy was given sequentially before and after trastuzumab, respectively, it was done concurrently with trastuzumab in the other four trials. As the HERA and FinHER studies had a lower incidence of cardiotoxicity, it remains possible that the concurrent use of radiotherapy and trastuzumab is cardiotoxic. On the other hand, however, an unplanned analysis of patients treated in the N9831 trial revealed no difference in the frequency of cardiac events between patients treated with or without radiotherapy even in the trastuzumab-containing arm . The delivery of radiation therapy concomitantly with trastuzumab is therefore generally considered safe.
4.7. Adjuvant Trastuzumab without Chemotherapy
Consideration has been given to the possibility of adjuvant trastuzumab therapy without chemotherapy, particularly when the patient is old or has a comorbidity, or the tumors are node-negative, ER- or PgR-positive, and small. In the metastatic setting, a phase III trial comparing anastrozole plus trastuzumab with anastrozole alone as first-line therapy for postmenopausal HER2- and hormone receptor-positive breast cancer showed combination therapy was superior in terms of progression-free survival (PFS) and response rate . However, the combination of endocrine therapy and trastuzumab without chemotherapy remains unproven in the adjuvant setting, and further data is accordingly needed before the elimination of chemotherapy can be justified. In this regard, a phase III trial comparing trastuzumab monotherapy with trastuzumab plus chemotherapy in HER2-positive elderly breast cancer patients is currently underway (NCT01104935).
5. Role of Lapatinib in Adjuvant Settings
5.1. Rationale of Lapatinib Use in Adjuvant Therapy for HER2-Positive Breast Cancer
Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor . In preclinical models, lapatinib has been shown to overcome resistance to trastuzumab, inhibiting phosphorylation of HER2 and overall growth in HER2-overexpressing breast cancer cell lines specifically selected for their in vitro resistance to trastuzumab . Additionally, lapatinib inhibited growth of cells that express HER2, which is truncated and lacks an extracellular domain and, therefore, has the potential to develop resistance to trastuzumab [60, 61]. Supporting the role of lapatinib as a backup drug for trastuzumab, a randomized phase III trial comparing capecitabine in combination with lapatinib to capecitabine alone in 399 patients with HER2-positive recurrent/metastatic breast cancer who had progressed with the anthracycline, taxane, and trastuzumab, reported that overall response was superior in the lapatinib-receiving arm (23.7% versus 13.9%; ), as was median time to progression (27.1 versus 18.6 weeks, ), while overall survival tended to be longer .
Unlike trastuzumab, lapatinib has been suggested to cross the blood-brain barrier, which rationalizes its use in patients with central nervous system (CNS) metastases. In a phase II trial of lapatinib in 39 patients with HER2-positive breast cancer with brain metastases, two patients experienced partial response based on the response evaluation criteria in solid tumors (RECISTs) criteria, and five additional patients experienced at least a 30% shrinkage of CNS lesions .
With regard to cardiac safety, prospective data collected in 44 clinical studies of lapatinib () revealed a low incidence of cardiac events potentially caused by lapatinib (1.6%) .
5.2. Rationale of Lapatinib in Combination with Trastuzumab
A preclinical study of lapatinib in combination with trastuzumab reported that survivin was more strongly downregulated and apoptosis was more strongly induced with this combination than with either agent alone . Another preclinical study showed that lapatinib alone or in combination with trastuzumab trastuzumab inhibited HER2 phosphorylation, prevented receptor ubiquitination, and resulted in the accumulation of inactive HER2 at the cell surface of HER2-overexpressing breast cancer cell lines, which led to the subsequent enhancement of ADCC by trastuzumab . Consistent with the preclinical data, a recent phase III clinical trial comparing lapatinib and trastuzumab in combination to lapatinib alone in HER2-positive metastatic breast cancer patients who had progressed on trastuzumab-based regimens reported that progression-free survival as the primary endpoint was better in the combination arm than in that with lapatinib alone (hazard ratio ; 95% CI, 0.57 to 0.93; ) . Furthermore, in the neoadjuvant lapatinib and/or trastuzumab treatment optimisation (Neo-ALTTO trial), 455 preoperative breast cancer patients with HER2-positive tumors received an initial 6 weeks of lapatinib, trastuzumab, or their combination, followed by another 12 weeks of the same anti-HER2 therapy plus wkly-PTX prior to definitive surgery. The first results, presented at the San Antonio Breast Cancer Symposium (SABCS) 2010, showed the highest pathological complete response (pCR) rate, the primary endpoint of the trial, in the combination arm (pCR rate [%]; lapatinib versus trastuzumab versus combination; 24.7 versus 29.5 versus 51.3; for lapatinib versus trastuzumab and for trastuzumab versus combination).
While this accumulating evidence supports the superiority of lapatinib and trastuzumab combination to either therapy alone, its role in adjuvant therapy remains to be revealed in the ALTTO study, as discussed below.
5.3. ALTTO Trial
The ALTTO trial is a large, randomized phase III trial designed to evaluate the role of lapatinib in adjuvant treatment for HER2-positive breast cancer patients (Figure 2) . Node-positive and node-negative patients with tumors ≥1.0 cm in greatest diameter were eligible, similar to the trials of adjuvant trastuzumab. Unlike these trials; however, HER2-positivity was evaluated following the ASCO/CAP guideline, so that patients with equivocal HER2-positivity were excluded. The ALTTO trial is comparing trastuzumab for 1 year as the reference arm with either lapatinib for 1 year, trastuzumab for 6 months followed by lapatinib for 6 months, and lapatinib in combination with trastuzumab for 1 year. This trial has two pragmatic designs; lapatinib and/or trastuzumab are given after the completion of anthracycline-based chemotherapy (Design 1, Figure 2), concomitantly with taxanes (Design 2, Figure 2), or with a nonanthracycline regimen (docetaxel plus carboplatin) (Design 2B, Figure 2). Designs 1, 2, and 2B were set referring to the HERA, NSABP B21 and NCCTG N9831, and BCIRG 006 trials, respectively. Designs 1 and 2 have already completed accrual, and Design 2B will complete accrual by early 2011. The results will provide answers about the role of lapatinib in adjuvant treatment for HER2-positive breast cancer.
6. Future Directions
6.1. Anti-HER2 Agents in HER2-Negative Population
In early clinical trials of trastuzumab for metastatic breast cancer, patients with HER2 2+ by IHC were enrolled together with HER2 3+ patients. Because subset analysis showed that the benefit of trastuzumab was none or smaller in HER2 2+ patients [5, 69], virtually all subsequent clinical trials of trastuzumab were limited to patients with HER2 3+ or FISH-positive disease.
In the NSABP B-31 trial, HER2 positivity was initially evaluated based on institutional testing, but excessive false positive HER2 results led to a change to mandatory confirmation by the central office . Among the 1787 patients with follow-up data in the trial, 174 patients had breast cancers that turned out to be HER2-negative (9.7%) on central review . Interestingly, these patients also appeared to benefit from trastuzumab (HR for disease-free survival, 0.34; 95% CI, 0.14 to 0.80; ) . Although this analysis was exploratory in a small subset, it at least raised a question of whether the benefit of adjuvant trastuzumab is really limited to patients with HER2-positivity based on today’s criteria.
Answering this question will require a phase III trial of adjuvant trastuzumab in women with breast cancers that do not meet established criteria. Additionally, refinement of HER2 testing methodology may be required. In their comparative analysis of 568 breast cancer tumor samples for HER2 with FISH according to the ASCO/CAP guideline and quantitative reverse transcriptase PCR (qRT-PCR) in central laboratories , Baehner et al found a high concordance rate of 97% (95% CI, 96%–99%) between the two methodologies . Given that qRT-PCR is faster than FISH and generally more quantitative than FISH or IHC, it might be a candidate for next-generation HER2 testing.
6.2. Newer Anti-HER2 Agents
Pertuzumab is another monoclonal antibody against the extracellular domain of HER2 protein, but it attaches to a different epitope of HER2 from trastuzumab. Pertuzumab is believed to inhibit heterodimer formation between HER2 and EGFR or HER3 . While the HER2/HER3 heterodimer is considered important in HER2-driven cell signaling, a preclinical study showed that the heregulin-dependent HER2/HER3 heterodimer is not disrupted by trastuzumab, but it is disrupted by pertuzumab . In a phase II clinical trial involving combination treatment with pertuzumab and trastuzumab in HER2-positive metastatic breast cancer patients, treatment produced a response rate and disease control rate of 24.2% and 50%, respectively . In the neoadjuvant setting, the neoadjuvant study of pertuzumab and herceptin in an early regimen evaluation (NeoSphere) trial randomized 417 patients with centrally confirmed HER2-positive breast cancer to either docetaxel plus trastuzumab (HD, reference arm, ), docetaxel, trastuzumab, and pertuzumab (HDP, ), pertuzumab plus trastuzumab (HP, ), or docetaxel plus pertuzumab (DP, ). Patients received four cycles of therapy prior to surgery. The results presented at SABCS 2010 showed that the pCR rate, the primary endpoint, was significantly higher in the HDP arm and lower in the HP arm compared to the reference HD arm (pCR rate [%]; HD versus HDP versus HP versus DP; 29.0 versus 45.8 versus 16.8 versus 24.0; for HD versus HDP). These studies suggest that the addition of pertuzumab to standard trastuzumab-based treatment might enhance efficacy in both metastatic and operable HER2-positive breast cancer.
Trastuzumab-DM1 is comprised of trastuzumab, DM1, an inhibitor of tubulin polymerization derived from maytansine, and the stable [N-maleimidomethyl]cyclohexane-1-carboxylate (MCC) linker that conjugates DM1 and trastuzumab. The compound is designed to efficiently deliver DM1 to HER2-overexpressing cancer cells. Preclinical studies have demonstrated the growth-inhibitory effect of trastuzumab-DM1 in HER2-overexpressing and trastuzumab-resistant cells . In a phase II trial involving HER2-positive metastatic breast cancer patients who had experienced disease progression despite trastuzumab-based therapy , trastuzumab-DM1 yielded a response rate and progression-free survival of 26.9% and 4.6 months, respectively . Importantly, trastuzumab-DM1 demonstrated similar antitumor activity and a response rate of 24.2% even in patients previously treated with lapatinib and trastuzumab . Feasibility and efficacy of trastuzumab-DM1 in adjuvant or neoadjuvant treatment for HER2-positive early breast cancer are currently under evaluation in a phase II study (NCT01196052).
6.2.3. HER2 Vaccines
Vaccines and adoptive immunotherapy targeting the HER2 extracellular domain have been tested in clinical trials, with results showing that significant levels of durable T-cell HER2 immunity can be generated with active immunization without significant autoimmunity consequences against normal tissues . Preliminary data from clinical trials testing the potential use of HER2 vaccines in adjuvant therapy for high-risk breast cancer patients have shown promising results .
The integration of trastuzumab into conventional adjuvant chemotherapy has significantly improved treatment outcomes in patients with HER2-positive early breast cancer. Although it is impossible to specify one particular regimen as superior, these trials suggest that anthracyclines followed by trastuzumab given concurrently with taxanes appear most promising albeit at the price of a relatively high incidence of cardiotoxicity. With the evidence available today, it is left to clinical judgment to determine whether patients with equivocal HER2-positivity based on ASCO/CAP or with a tumor size of 0.6 to 1.0 cm should be given trastuzumab, and what level of cardiac risk warrants less cardiotoxic trastuzumab regimens, namely, those with a shorter duration of trastuzumab, sequential use, and the avoidance of anthracyclines. The ALTTO trial will clarify the role of lapatinib in adjuvant treatment for HER2-positive breast cancer, as it is or in combination with trastuzumab. Role of newer class of anti-HER2 agent in adjuvant treatment for breast cancer will also be evaluated in clinic in the near future.
- K. McPherson, C. M. Steel, and J. M. Dixon, “ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics,” British Medical Journal, vol. 321, no. 7261, pp. 624–628, 2000.
- D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.
- D. J. Slamon, W. Godolphin, L. A. Jones et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 707–712, 1989.
- D. J. Slamon, G. M. Clark, S. G. Wong, et al., “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987.
- D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001.
- H. J. Burstein, A. Keshaviah, A. D. Baron et al., “Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study,” Cancer, vol. 110, no. 5, pp. 965–972, 2007.
- M. Jahanzeb, J. E. Mortimer, F. Yunus et al., “Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer,” Oncologist, vol. 7, no. 5, pp. 410–417, 2002.
- G. Von Minckwitz, A. Du Bois, M. Schmidt et al., “Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 1999–2006, 2009.
- M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005.
- E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005.
- D. Slamon, W. Eiermann, N. Robert, et al., “Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2006.
- D. Slamon, W. Eiermann, N. Robert, et al., “Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: third planned efficacy analysis,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2009.
- E. A. Perez, E. H. Romond, V. J. Suman, et al., “Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer,” Journal of Clinical Oncology, vol. 25, no. 18S, p. 512, 2007.
- I. Smith, M. Procter, R. D. Gelber et al., “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial,” The Lancet, vol. 369, no. 9555, pp. 29–36, 2007.
- H. Joensuu, P. Bono, V. Kataja et al., “Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5685–5692, 2009.
- H. Joensuu, P. L. Kellokumpu-Lehtinen, P. Bono et al., “Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer,” The New England Journal of Medicine, vol. 354, no. 8, pp. 809–820, 2006.
- C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006.
- F. Lonardo, E. Di Marco, C. R. King et al., “The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand,” New Biologist, vol. 2, no. 11, pp. 992–1003, 1990.
- J. H. Pierce, P. Arnstein, E. DiMarco et al., “Oncogenic potential of erbB-2 in human mammary epithelial cells,” Oncogene, vol. 6, no. 7, pp. 1189–1194, 1991.
- C. Wallasch, F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, and A. Ullrich, “Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3,” EMBO Journal, vol. 14, no. 17, pp. 4267–4275, 1995.
- K. Zhang, J. Sun, N. Liu et al., “Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2,” Journal of Biological Chemistry, vol. 271, no. 7, pp. 3884–3890, 1996.
- R. Pinkas-Kramarski, A. E. G. Lenferink, S. S. Bacus et al., “The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin,” Oncogene, vol. 16, no. 10, pp. 1249–1258, 1998.
- M. Alimandi, A. Romano, M. C. Curia et al., “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas,” Oncogene, vol. 10, no. 9, pp. 1813–1821, 1995.
- M. Tan, J. Yao, and D. Yu, “Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities,” Cancer Research, vol. 57, no. 6, pp. 1199–1205, 1997.
- D. Yu, B. Liu, M. Tan, J. Li, S. S. Wang, and M. C. Hung, “Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms,” Oncogene, vol. 13, no. 6, pp. 1359–1365, 1996.
- C. Knuefermann, Y. Lu, B. Liu et al., “HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells,” Oncogene, vol. 22, no. 21, pp. 3205–3212, 2003.
- D. C. Allred, G. M. Clark, A. K. Tandon et al., “HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma,” Journal of Clinical Oncology, vol. 10, no. 4, pp. 599–605, 1992.
- B. A. Gusterson, R. D. Gelber, A. Goldhirsch, et al., “Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group,” Journal of Clinical Oncology, vol. 10, no. 7, pp. 1049–1056, 1992.
- T. Holbro, R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas, and N. E. Hynes, “The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8933–8938, 2003.
- S. Ménard, S. M. Pupa, M. Campiglio, and E. Tagliabue, “Biologic and therapeutic role of HER2 in cancer,” Oncogene, vol. 22, no. 43, pp. 6570–6578, 2003.
- I. Rubin and Y. Yarden, “The basic biology of HER2,” Annals of Oncology, vol. 12, supplement 1, pp. S3–S8, 2001.
- T. T. Junttila, R. W. Akita, K. Parsons et al., “Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941,” Cancer Cell, vol. 15, no. 5, pp. 429–440, 2009.
- S. T. Lee-Hoeflich, L. Crocker, E. Yao et al., “A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy,” Cancer Research, vol. 68, no. 14, pp. 5878–5887, 2008.
- Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami, “Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines,” Annals of Oncology, vol. 21, no. 2, pp. 255–262, 2010.
- K. Berns, H. M. Horlings, B. T. Hennessy et al., “A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer,” Cancer Cell, vol. 12, no. 4, pp. 395–402, 2007.
- Y. Nagata, K. H. Lan, X. Zhou et al., “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients,” Cancer Cell, vol. 6, no. 2, pp. 117–127, 2004.
- N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005.
- R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000.
- K. S. Albain, W. E. Barlow, P. M. Ravdin et al., “Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 374, no. 9707, pp. 2055–2063, 2009.
- A. Howell, J. Cuzick, M. Baum, et al., “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer,” The Lancet, vol. 365, no. 9453, pp. 60–62, 2005.
- E. A. Perez, V. J. Suman, N. E. Davidson, et al., “Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2009.
- E. A. Perez, M. M. Reinholz, A. C. Dueck, et al., “Do the ASCO/CAP 2007 HER2 testing guidelines improve prediction of benefit to adjuvant trastuzumab? Data from North Central Cancer Treatment Group N9831 Adjuvant Trial,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2009.
- L. G. Gianni, U. Dafni, R. D. Gelber, et al., “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial,” The Lancet Oncology, vol. 12, no. 3, pp. 236–244, 2011.
- M. Spielmann, H. Roché, T. Delozier et al., “Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial,” Journal of Clinical Oncology, vol. 27, no. 36, pp. 6129–6134, 2009.
- A. C. Wolff, M. E. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 1, pp. 18–43, 2007.
- A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thürlimann, and H. J. Senn, “Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009,” Annals of Oncology, vol. 20, no. 8, pp. 1319–1329, 2009.
- A. M. Gonzalez-Angulo, J. K. Litton, K. R. Broglio et al., “High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5700–5706, 2009.
- G. Curigliano, G. Viale, V. Bagnardi et al., “Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5693–5699, 2009.
- B. Norris, S. Chia, and M. Cheang, “Poor 10 yr breast cancer specific survival and relapse free survival for HER2 positive T1N0 tumors,” in Proceedings of the Annual San Antonio Breast Cancer Symposium (SABCS '09), San Antonio, Tex, USA, December 2006.
- S. Banerjee and I. E. Smith, “Management of small HER2-positive breast cancers,” The Lancet Oncology, vol. 11, no. 12, pp. 1193–1199, 2010.
- M. S. Ewer and S. M. Lippman, “Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 2900–2902, 2005.
- M. S. Ewer, M. T. Vooletich, J. B. Durand et al., “Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7820–7826, 2005.
- S. M. Ewer and M. S. Ewer, “Cardiotoxicity profile of trastuzumab,” Drug Safety, vol. 31, no. 6, pp. 459–467, 2008.
- E. Tan-Chiu, G. Yothers, E. Romond et al., “Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7811–7819, 2005.
- E. A. Perez, V. J. Suman, N. E. Davidson et al., “Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1231–1238, 2008.
- M. Y. Halyard, T. M. Pisansky, A. C. Dueck et al., “Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2638–2644, 2009.
- B. Kaufman, J. R. Mackey, M. R. Clemens et al., “Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study,” Journal of Clinical Oncology, vol. 27, no. 33, pp. 5529–5537, 2009.
- D. W. Rusnak, K. Lackey, K. Affleck et al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 1, no. 2, pp. 85–94, 2001.
- G. E. Konecny, M. D. Pegram, N. Venkatesan et al., “Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells,” Cancer Research, vol. 66, no. 3, pp. 1630–1639, 2006.
- W. Xia, L. H. Liu, P. Ho, and N. L. Spector, “Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016,” Oncogene, vol. 23, no. 3, pp. 646–653, 2004.
- M. Scaltriti, F. Rojo, A. Ocaña et al., “Expression of p95HER2, a truncated form of the HER2 receptor, and response to Anti-HER2 therapies in breast cancer,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 628–638, 2007.
- D. Cameron, M. Casey, M. Press et al., “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 533–543, 2008.
- N. U. Lin, L. A. Carey, M. C. Liu, et al., “Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer,” Journal of Clinical Oncology, vol. 24, no. 18S, p. 503, 2006.
- E. A. Perez, M. Koehler, J. Byrne, A. J. Preston, E. Rappold, and M. S. Ewer, “Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials,” Mayo Clinic Proceedings, vol. 83, no. 6, pp. 679–686, 2008.
- W. Xia, C. M. Gerard, L. Liu, N. M. Baudson, T. L. Ory, and N. L. Spector, “Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells,” Oncogene, vol. 24, no. 41, pp. 6213–6221, 2005.
- M. Scaltriti, C. Verma, M. Guzman et al., “Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity,” Oncogene, vol. 28, no. 6, pp. 803–814, 2009.
- K. L. Blackwell, H. J. Burstein, A. M. Storniolo et al., “Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1124–1130, 2010.
- B. Moy and P. E. Goss, “Lapatinib: current status and future directions in breast cancer,” Oncologist, vol. 11, no. 10, pp. 1047–1057, 2006.
- C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002.
- S. Paik, J. Bryant, E. Tan-Chiu et al., “Rela-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience,” Journal of the National Cancer Institute, vol. 94, no. 11, pp. 852–854, 2002.
- S. Paik, C. Kim, and N. Wolmark, “HER2 status and benefit from adjuvant trastuzumab in breast cancer,” The New England Journal of Medicine, vol. 358, no. 13, pp. 1409–1411, 2008.
- F. L. Baehner, N. Achacoso, T. Maddala et al., “Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4300–4306, 2010.
- D. B. Agus, R. W. Akita, W. D. Fox et al., “Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth,” Cancer Cell, vol. 2, no. 2, pp. 127–137, 2002.
- J. Baselga, K. A. Gelmon, S. Verma et al., “Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1138–1144, 2010.
- G. D. Lewis Phillips, G. Li, D. L. Dugger et al., “Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate,” Cancer Research, vol. 68, no. 22, pp. 9280–9290, 2008.
- C. L. Vogel, H. A. Burris, S. Limentani, et al., “A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results,” Journal of Clinical Oncology, vol. 27, abstract 1017, supplement, p. 15s, 2009.
- H. Bernhard, L. Salazar, K. Schiffman et al., “Vaccination against the HER-2/neu oncogenic protein,” Endocrine-Related Cancer, vol. 9, no. 1, pp. 33–44, 2002.
- G. E. Peoples, J. P. Holmes, M. T. Hueman et al., “Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group study I-01 and I-02,” Clinical Cancer Research, vol. 14, no. 3, pp. 797–803, 2008.